NCT04252430View on ClinicalTrials.gov

RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions
Healthy VolunteersImpaired Renal Function
Interventions
DRUG

MD1003

Single oral dose administration of MD1003 at Day 1

Trial Locations (5)

1083

Semmelweis University Faculty of Medicine, Budapest

3528

Clinical Research Units Hungary Ltd., Miskolc

4032

University of Debrecen Medical and Health Center, Debrecen

8231

DRC Drug Research Center Ltd., Balatonfüred

38610

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
collaborator

Eurofins Optimed

INDUSTRY

lead

MedDay Pharmaceuticals SA

INDUSTRY

NCT04252430 - RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects | Biotech Hunter | Biotech Hunter